Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
alnylam pharmaceuticals
boston
3
×
boston blog main
boston top stories
drugs
life sciences
national blog main
aminolevulinic acid
clinical trials
fda
givosiran
onpattro
patisiran
rna interference
accelerated approval
acute hepatic porphyria
acute hepatic porphyrias
akcea therapeutics
akin akinc
european medicines agency
harvard pilgrim health care
hereditary transthyretin amyloidosis
inotersen
institute for clinical and economic review
national top stories
new york blog main
new york top stories
paul matteis
pfizer
san diego blog main
san diego top stories
stifel financial
tafamidis
What
alnylam
3
×
drug
interference
medicine
rna
3
×
rnai
3
×
fda
pharmaceuticals
second
seek
speedy
ago
approval
approves
cells
cleared
data
ema
employ
europe
far
follows
gene
harmful
hits
indicated
make
market
method
mute
nasdaq
new
nod
ok
protein
quick
uses
way
weeks
won’t
Language
Current search:
rnai
×
rna
×
alnylam
×
boston
×
@xconomy.com
5 years ago
Alnylam Won’t Seek Quick FDA Nod For Second RNAi Drug
@xconomy.com
5 years ago
With New Data, Alnylam Could Seek Speedy OK For Second RNAi Drug
@xconomy.com
5 years ago
RNAi Hits Europe as EMA Follows FDA, Approves Alnylam Drug